Get started
Author

Serge Moudio

Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives
2020 · Alexandra L Degraeve, Serge Moudio, et al. · Expert Opinion on Drug Metabolism & Toxicology · 53
Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study
2023 · Alexandra L. Degraeve, Laure B. Bindels, et al. · Clinical Pharmacology & Therapeutics · 32
Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes
2022 · L. Pavelka, A. Rauschenberger, et al. · npj Parkinson s Disease · 28
PDF
Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
2016 · Trevor Bushell, Margaret Cunningham, et al. · Current Drug Targets · 22
A Population Pharmacokinetic Model and Dosing Algorithm to Guide the Tacrolimus Starting and Follow-Up Dose in Living and Deceased Donor Kidney Transplant Recipients
2025 · Marith I. Francke, Sebastiaan D. T. Sassen, et al. · Clinical Pharmacokinetics · 11
PDF
Exposure of α-Synuclein Aggregates to Organotypic Slice Cultures Recapitulates Key Molecular Features of Parkinson's Disease
2022 · Serge Moudio, Fredrik Rodin, et al. · Frontiers in Neurology · 11
PDF
Protease-activated receptor 2 activation induces behavioural changes associated with depression-like behaviour through microglial-independent modulation of inflammatory cytokines
2021 · Serge Moudio, Ashleigh Willis, et al. · Psychopharmacology · 10
Neuroprotection induced by protease-activated receptor 2 activation is independent of Gq signalling
2025 · Serge Moudio, Hugh N. Nuthall, et al. · Brain and Neuroscience Advances · 1
Publisher Correction: Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes
2022 · L. Pavelka, A. Rauschenberger, et al. · npj Parkinson s Disease · 1
PDF
EE129 Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium
2025 · Rucha Vadia, Edgard Prihadi, et al. · Value in Health
Investigating the neuroprotective properties of PAR2
2016 · Moudio, Serge M. · STAX
Works count: 11
Citation count: 169
H-index: 7
I10-index: 7
Year
Topic
Type